Clinical Trials · NCT00472901
Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Clinuvel Pharmaceuticals Limited
- Enrollment
- 18
- Start date
- May 2007
- Locations
- 3 sites, 3 countries
- Primary endpoint
- To evaluate whether afamelanotide (CUV1647) prevents episodes or reduces the severity of PLE symptoms in patients with a well documented history of PLE